Lia Mix sits down with Dr. Will VanDerveer, psychiatrist, co-founder of the Integrative Psychiatry Institute and Integrative Psychiatry Centers, and co-author of the New York Times bestseller Psychedelic Therapy, to discuss the evolution of integrative and psychedelic-assisted psychiatry.
Our tenth Insight Session explored ibogaine through clinical, cultural, and consciousness-focused lenses, examining why the compound continues to occupy a unique position within the psychedelic field.
Lia Mix sits down with Dr. Leith States and Ryan Roberts to discuss what the federal psychedelic executive order means in practice, where it may accelerate progress, and what still stands between policy signal and real patient access.
The definitive read on the Executive Order on psychedelic therapies signed on April 18th, 2026 by Delphi and the Ibogaine Healthcare Policy Institute (IHPI).
Lia Mix sits down with Floris Wolswijk, founder of Blossom, to discuss how psychedelic research can be made more usable for the people shaping the field.
Lia Mix and Britt Rollins discuss insurance, infrastructure, and what it will take to scale psychedelic care safely.
Welcome and Introduction of Melissa Lavasani Lia Mix: Hello, everyone, and welcome. I am Lia Mix, the CEO of Delphi, and we are excited to have you for our monthly insight session. Today, we welcome Melissa Lavasani, the founder and CEO of the Psychedelic Medicine Coalition (PMC). PMC is the only Washington, D.C.-based nonprofit dedicated to advancing psychedelic-assisted therapies at the federal level. A nationally recognized policy leader, Melissa authored and led the passage of Washington, D.C.’s Initiative 81, the Entheogenic Plant and Fungus Policy Act of 2020. This passed with 76 percent voter approval, motivated by her personal experience using psychedelic medicines to recover from severe postpartum depression. Under her leadership, PMC has built bipartisan support in Congress and advanced key federal legislation through the Congressional Psychedelics Advancing Therapies (PATH) Caucus. This includes the Innovative Therapies Centers for Excellence Act and the Expanding Veterans Access to Emerging Treatments Act.
In this Delphi Insight Session, Dr Leith States discusses psychedelic-assisted therapies and ibogaine and how they can impact public health.
This month, the strongest policy signal is that access is being built from multiple directions at once. Texas is using state dollars to stand up an ibogaine clinical trial consortium, federal lawmakers are trying to unlock a pre-approval access pathway for Schedule I psychedelics, and health systems abroad are moving from “permission” to “payment” with tighter delivery rules.
December 2025’s studies add practical detail to a shift already underway: psychedelic care is moving from “can it work” to “how do we deliver it safely, consistently, and in a way payers can cover.”
